Alejandro Martínez‐Bueno

942 total citations · 1 hit paper
26 papers, 415 citations indexed

About

Alejandro Martínez‐Bueno is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Alejandro Martínez‐Bueno has authored 26 papers receiving a total of 415 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Alejandro Martínez‐Bueno's work include Cancer Treatment and Pharmacology (8 papers), Advanced Breast Cancer Therapies (5 papers) and Liquid Crystal Research Advancements (5 papers). Alejandro Martínez‐Bueno is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Advanced Breast Cancer Therapies (5 papers) and Liquid Crystal Research Advancements (5 papers). Alejandro Martínez‐Bueno collaborates with scholars based in Spain, Italy and United States. Alejandro Martínez‐Bueno's co-authors include Teresa Sierra, Javier Cortés, María Gión, Salvador Blanch, Miguel Sampayo-Cordero, Antonio Llombart‐Cussac, Juan de la Haba-Rodríguez, Juan Miguel Cejalvo, Andrea Malfettone and José Manuel Pérez-García and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Chemistry of Materials.

In The Last Decade

Alejandro Martínez‐Bueno

24 papers receiving 410 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial

2022 162 citations José Manuel Pérez-García, Marta Vaz Batista et al. Neuro-Oncology profile →

Peers

Countries citing papers authored by Alejandro Martínez‐Bueno

Since Specialization

Citations

This map shows the geographic impact of Alejandro Martínez‐Bueno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alejandro Martínez‐Bueno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alejandro Martínez‐Bueno more than expected).

Fields of papers citing papers by Alejandro Martínez‐Bueno

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alejandro Martínez‐Bueno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alejandro Martínez‐Bueno. The network helps show where Alejandro Martínez‐Bueno may publish in the future.

Co-authorship network of co-authors of Alejandro Martínez‐Bueno

This figure shows the co-authorship network connecting the top 25 collaborators of Alejandro Martínez‐Bueno. A scholar is included among the top collaborators of Alejandro Martínez‐Bueno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alejandro Martínez‐Bueno. Alejandro Martínez‐Bueno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Unveiling Adenine H-bonded Hexads: Hierarchical Self-Assembly for Helical Columnar Functional Materials 2025 ·JACS Au ·Alejandro Martínez‐Bueno, (unknown), Roberto Termine, Attilio Golemme, J. Ortega, C. L. Folcia, José M. Granadino‐Roldán, Amparo Navarro, Raquel Giménez, Teresa Sierra	0
2	Photo‐regenerable liquid crystalline polymers for the adsorption of organic pollutants 2025 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Giusy Curcuruto, (unknown), Alejandro Martínez‐Bueno, (unknown), (unknown), G. Impellizzeri, Paola Lova, Martina Salzano de Luna, Daniele Martella	0
3	Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial 2025 ·EClinicalMedicine ·(unknown), María Gión, Manuel Ruíz‐Borrego, Isabel Blancas, (unknown), Salvador Blanch, Sabela Recalde, (unknown), Xavier González, (unknown), Serafín Morales, (unknown), (unknown), (unknown), José Antonio López‐Guerrero, Miguel Sampayo-Cordero, Alejandro Martínez‐Bueno, Javier Cortés, Antonio Llombart‐Cussac	1
4	Abstract P1-02-06: Efficacy analysis & updated safety from the phase 2 PRIMED study of prophylactic granulocyte-colony stimulating factor (G-CSF) & loperamide for patients (pts) with HER2-negative advanced breast cancer (ABC) treated w/ sacituzumab govitecan (SG) 2025 ·Clinical Cancer Research ·María Gión, Manuel Ruíz‐Borrego, (unknown), (unknown), Salvador Blanch, Sabela Recalde, Lourdes Calvo, Xavier González, (unknown), Serafín Morales, (unknown), (unknown), (unknown), José A. Guerrero, Miguel Sampayo-Cordero, Alejandro Martínez‐Bueno, Javier Cortés, Antonio Llombart‐Cussac	1
5	Chiral ferroelectric nematic liquid crystals as materials for versatile laser devices 2024 ·Giant ·C. L. Folcia, J. Ortega, Teresa Sierra, Alejandro Martínez‐Bueno, J. Etxebarría	8
6	Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial. 2024 ·Journal of Clinical Oncology ·José Manuel Pérez García, María Gión, Manuel Ruíz‐Borrego, (unknown), (unknown), Salvador Blanch, Sabela Recalde, Lourdes Calvo, Xavier González, (unknown), Serafín Morales, (unknown), (unknown), (unknown), José Antonio López‐Guerrero, Miguel Sampayo-Cordero, Alejandro Martínez‐Bueno, Javier Cortés, Antonio Llombart‐Cussac	11
7	Effect of Hydrogen Bonding and Chirality in Star-Shaped Molecules with Peripheral Triphenylamines: Liquid Crystal Semiconductors and Gels 2024 ·Chemistry of Materials ·Alejandro Martínez‐Bueno, Santiago Martı́n, J. Ortega, C. L. Folcia, Roberto Termine, Attilio Golemme, Raquel Giménez, Teresa Sierra	4
8	Efficacy and genomic analysis of HER2-mutant, metastatic triple-negative breast cancer treated with neratinib alone or in combination with trastuzumab in the phase 2 SUMMIT basket trial. 2024 ·Journal of Clinical Oncology ·Komal Jhaveri, Sara A. Hurvitz, Adam Brufsky, Ron Bose, Maria J. de Miguel, Ella Evron, Nisha Unni, Sonya Reid, David I. Quinn, Devalingam Mahalingam, Cristina Saura, José Á. García-Sáenz, Alejandro Martínez‐Bueno, Ángel Guerrero, Christelle de la Fouchardière, Hans Wildiers, G. Bischof, Judith D. Bebchuk, Lisa D. Eli, David B. Solit	1
9	Triphenylamine-Containing Benzoic Acids: Synthesis, Liquid Crystalline and Redox Properties 2023 ·Molecules ·(unknown), Alejandro Martínez‐Bueno, Teresa Sierra, Raquel Giménez	4
10	Soft nanostructures out of star-shaped triazines with flexible amide spacers: liquid crystals with a cubic to columnar transition with memory effect, gels and supramolecular chirality 2023 ·Materials Today Chemistry ·Alejandro Martínez‐Bueno, (unknown), J. Ortega, J. Etxebarría, C. L. Folcia, Raquel Giménez, Teresa Sierra	6
11	Abstract PD7-02: Trastuzumab Deruxtecan in patients with Unstable Central Nervous System Involvement from HER2-Low Advanced Breast Cancer: The DEBBRAH Trial 2023 ·Cancer Research ·José Manuel Pérez-García, Marta Vaz Batista, (unknown), Manuel Ruíz Borrego, Juan Miguel Cejalvo, Juan de la Haba-Rodríguez, Laia Garrigós, (unknown), (unknown), Salvador Blanch, María Gión, Mónica Nave, (unknown), Alejandro Martínez‐Bueno, Antonio Llombart‐Cussac, Miguel Sampayo-Cordero, Andrea Malfettone, Javier Cortés, Sofía Braga	6
12	Fluorescence In Situ Hybridization (FISH) for the Characterization and Monitoring of Primary Cultures from Human Tumors 2023 ·SHILAP Revista de lepidopterología ·(unknown), Cristina Aguado, Núria Jordana‐Ariza, (unknown), Sonia Rodrı́guez, Erika Aldeguer, (unknown), Beatriz García‐Peláez, Marta Vives-Usano, Ana Giménez‐Capitán, Andrés Aguilar, Alejandro Martínez‐Bueno, María González Cao, (unknown), Santiago Viteri, (unknown), Rafael Rosell, Miguel Ángel Molina‐Vila	1
13	Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial breakdown → 2022 ·Neuro-Oncology ·José Manuel Pérez-García, Marta Vaz Batista, (unknown), Manuel Ruíz‐Borrego, Juan Miguel Cejalvo, Juan de la Haba-Rodríguez, Laia Garrigós, (unknown), (unknown), Salvador Blanch, María Gión, Mónica Nave, María Fernández, Alejandro Martínez‐Bueno, Antonio Llombart‐Cussac, Miguel Sampayo-Cordero, Andrea Malfettone, Javier Cortés, Sofía Braga	162
14	Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study 2022 ·Cancers ·(unknown), Sonia Del Barco Berrón, (unknown), (unknown), (unknown), Alfonso Cortés, Pedro Sánchez‐Rovira, Alejandro Martínez‐Bueno, Xavier González, (unknown), Petra Gener, Leonardo Mina, Daniel Alcalá-López, (unknown), Javier Cortés, José Manuel Pérez-García, Antonio Llombart‐Cussac, (unknown)	2
15	Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (MET^Amp/Ex14∆). 2020 ·Journal of Clinical Oncology ·D. Ross Camidge, Filip Jankú, Alejandro Martínez‐Bueno, Daniel V.T. Catenacci, Jeeyun Lee, Se‐Hoon Lee, Afshin Dowlati, Kristoffer Staal Rohrberg, Alejandro Navarro, Yong Wha Moon, Mark M. Awad, Rebecca S. Heist, (unknown), Arielle Yablonovitch, (unknown), (unknown), (unknown), Debra L. Wood, Rita P. Dalal, Enriqueta Felip	28
16	Beyond liquid crystals: new research trends for mesogenic molecules in liquids 2019 ·Journal of Materials Chemistry C ·(unknown), Alejandro Martínez‐Bueno, Raquel Giménez, Teresa Sierra, M. Blanca Ros	33
17	Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients 2017 ·British Journal of Cancer ·Umberto Malapelle, (unknown), Danilo Rocco, Mónica Garzón, Pasquale Pisapia, Núria Jordana‐Ariza, Maria Russo, Roberta Sgariglia, Caterina De Luca, Francesco Pepe, Alejandro Martínez‐Bueno, Daniela Morales-Espinosa, María González‐Cao, Niki Karachaliou, Santiago Viteri, Claudio Bellevicine, Miguel Ángel Molina‐Vila, Rafael Rosell, Giancarlo Troncone	95
18	Association of p53 mutations with progression-free survival (PFS) and overall survival (OS) in EGFR-mutated non-small cell lung cancer (NSCLC) patients (p) treated with erlotinib. 2012 ·Journal of Clinical Oncology ·Amaya Gascó, Miguel Ángel Molina‐Vila, Jordi Bertrán-Alamillo, Clara Mayo, Carlota Costa, Ana Giménez‐Capitán, Bartomeu Massutí, Carlos Camps, Enric Carcereny, Santiago Viteri, Alejandro Martínez‐Bueno, Susana Benlloch, Lluís Capdevila, (unknown), Rut Porta, Felipe Cardenal, Joaquim Bosch‐Barrera, José Javier Sánchez, Miquel Tarón, Rafael Rosell	3
19	Elderly patients with advanced non-small cell lung cancer (nsclc). Results of chemotherapy and comparison with younger patients 2006 ·Journal of Clinical Oncology ·(unknown), Alejandro Martínez‐Bueno, Guillermo López-Vivanco, N. Fuente, Ramón Barceló, (unknown), (unknown), (unknown), Ricardo Fernández, Alberto Múñoz	2
20	Concurrent chemoradiotherapy (crt) with weekly docetaxel (d) for advanced head and neck cancer 2006 ·Journal of Clinical Oncology ·(unknown), Guillermo López-Vivanco, Ricardo Fernández, (unknown), (unknown), (unknown), Alejandro Martínez‐Bueno, (unknown), Alberto Múñoz, Ramón Barceló	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact